NEXALIN TECHNOLOGY INC (NXL)
US65345B2016 - Common Stock
Taking everything into account, NXL scores 3 out of 10 in our fundamental rating. NXL was compared to 188 industry peers in the Health Care Equipment & Supplies industry. No worries on liquidiy or solvency for NXL as it has an excellent financial health rating, but there are worries on the profitability. NXL is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year NXL has reported negative net income.
In the past year NXL has reported a negative cash flow from operations.
In the past 5 years NXL always reported negative net income.
In the past 5 years NXL always reported negative operating cash flow.
1.2 Ratios
NXL's Return On Assets of -345.87% is on the low side compared to the rest of the industry. NXL is outperformed by 95.72% of its industry peers.
With a Return On Equity value of -400.17%, NXL is not doing good in the industry: 87.17% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -345.87% | ||
| ROE | -400.17% | ||
| ROIC | N/A |
ROA(3y)-320.51%
ROA(5y)-1671.7%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 85.18%, NXL belongs to the best of the industry, outperforming 96.26% of the companies in the same industry.
In the last couple of years the Gross Margin of NXL has declined.
The Profit Margin and Operating Margin are not available for NXL so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 85.18% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.25%
GM growth 5YN/A
2. Health
2.1 Basic Checks
NXL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NXL has more shares outstanding
There is no outstanding debt for NXL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 33.05 indicates that NXL is not in any danger for bankruptcy at the moment.
NXL has a better Altman-Z score (33.05) than 96.79% of its industry peers.
There is no outstanding debt for NXL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 33.05 |
ROIC/WACCN/A
WACC9.03%
2.3 Liquidity
NXL has a Current Ratio of 5.57. This indicates that NXL is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of NXL (5.57) is better than 76.47% of its industry peers.
A Quick Ratio of 4.89 indicates that NXL has no problem at all paying its short term obligations.
NXL has a Quick ratio of 4.89. This is in the better half of the industry: NXL outperforms 76.47% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.57 | ||
| Quick Ratio | 4.89 |
3. Growth
3.1 Past
NXL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -113.61%.
Looking at the last year, NXL shows a very negative growth in Revenue. The Revenue has decreased by -77.87% in the last year.
The Revenue for NXL have been decreasing by -22.72% on average. This is quite bad
EPS 1Y (TTM)-113.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-55.75%
Revenue 1Y (TTM)-77.87%
Revenue growth 3Y-22.72%
Revenue growth 5YN/A
Sales Q2Q%-32.9%
3.2 Future
Based on estimates for the next years, NXL will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.39% on average per year.
NXL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 163.23% yearly.
EPS Next Y21.68%
EPS Next 2Y15.96%
EPS Next 3Y15.39%
EPS Next 5YN/A
Revenue Next Year51.39%
Revenue Next 2Y104.82%
Revenue Next 3Y163.23%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
NXL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NXL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as NXL's earnings are expected to grow with 15.39% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.96%
EPS Next 3Y15.39%
5. Dividend
5.1 Amount
NXL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NEXALIN TECHNOLOGY INC
NASDAQ:NXL (11/22/2024, 8:00:02 PM)
After market: 3.85 +0.03 (+0.79%)3.82
-0.08 (-2.05%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap49.13M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -345.87% | ||
| ROE | -400.17% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 85.18% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.09
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 5.57 | ||
| Quick Ratio | 4.89 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-113.61%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y21.68%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-77.87%
Revenue growth 3Y-22.72%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y